<DOC>
	<DOCNO>NCT00039780</DOCNO>
	<brief_summary>The purpose study determine whether BNP7787 effective prevent reduce neurotoxicity ( nerve damage ) cause paclitaxel ( Taxol® ) .</brief_summary>
	<brief_title>Evaluation BNP7787 Prevention Neurotoxicity Metastatic Breast Cancer Patients Receiving Weekly Paclitaxel</brief_title>
	<detailed_description>Chemotherapy induced toxicity common serious problem many patient receive treatment cancer . Chemotherapy induced toxicity adversely impact quality life ability patient continue treatment cancer . One toxicity associate use paclitaxel ( Taxol® ) peripheral neurotoxicity . Paclitaxel active drug treatment metastatic breast cancer first-line treatment patient recurrent refractory disease , include patient fail respond previous anthracycline therapy . Recent study paclitaxel use weekly schedule administration demonstrate high tumor response rate disease free survival accompany shift frequency certain toxicity , increase dose intensity potential mean improve treatment schedule paclitaxel improve patient benefit . Paclitaxel induced neurotoxicity remain important problem limit ability improve schedule administration drug . To date , effective FDA approve therapy prevent development reduce frequency severity paclitaxel-induced neurotoxicity . BNP7787 investigational new drug undergoing development chemoprotection platinum taxane associate common clinical toxicity , particularly prevention chemotherapy-induced neurotoxicity . In Phase 3 clinical trial safety effectiveness BNP7787 prevent mitigate frequency , severity , worsen grade , time onset , duration discontinuation therapy due paclitaxel-induced neurotoxicity assess patient metastatic breast cancer .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neurotoxicity Syndromes</mesh_term>
	<mesh_term>Breast Diseases</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Mesna</mesh_term>
	<criteria>INCLUSION CRITERIA Histologically cytologically document metastatic breast cancer Measurable disease Performance Status ; ECOG 02 More 2 week since prior radiation therapy 14 day since prior therapy recover side effect For patient progress receive hormonal therapy alone , patient may enrol study soon recover side effect hormonal therapy Clinical laboratory value must meet following : Granulocytes great equal 1,500/mm ( 3 ) Platelets great equal 100,000/mm ( 3 ) Hemoglobin great equal 9 g/dL SGOT le 2.0 x ULN Bilirubin less equal 1.5 mg/dL Creatinine le equal 1.6 mg/dL Calcium le ULN EXCLUSION CRITERIA Current CNS metastases history CNS metastases History diabetes ( Type I Type II ) Previous concurrent malignancy except : inactive nonmelanoma skin cancer situ carcinoma cervix cancer patient diseasefree 5 year Pregnant lactating woman History recent myocardial infarction , stroke , uncontrolled CHF , epilepsy , hypertension Patients currently receive Neurontin® ( gabapentin ) , glutamine supplement , Elavil® ( amitriptyline ) , Dilantin® , Tegretol® , tricyclic antidepressant similar medication study period Alternative medication include megadose vitamin , herbal preparation , tonic , extract , etc . allow study period .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Breast</keyword>
	<keyword>Cancer</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Peripheral</keyword>
	<keyword>Taxol</keyword>
	<keyword>Neuropathy</keyword>
	<keyword>Neurotoxicity</keyword>
	<keyword>Paresthesias</keyword>
	<keyword>Weekly</keyword>
	<keyword>BNP7787</keyword>
	<keyword>7787</keyword>
	<keyword>Tavocept</keyword>
	<keyword>Prevention</keyword>
</DOC>